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Abstract
Studying the mechanism(s) of uterine relaxation is important and will be helpful in the prevention
of obstetric difficulties such as preterm labour, which remains a major cause of perinatal mortality
and morbidity. Multiple signalling pathways regulate the balance between maintaining relative
uterine quiescence during gestation, and the transition to the contractile state at the onset of
parturition. Elevation of intracellular cyclic AMP promotes myometrial relaxation, and thus
quiescence, via effects on multiple intracellular targets including calcium channels, potassium
channels and myosin light chain kinase. A complete understanding of cAMP regulatory pathways
(synthesis and hydrolysis) would assist in the development of better tocolytics to delay or inhibit
preterm labour. Here we review the enzymes involved in cAMP homoeostasis (adenylyl cyclases
and phosphodiesterases) and possible myometrial substrates for the cAMP dependent protein
kinase. We must emphasise the need to identify novel pharmacological targets in human pregnant
myometrium to achieve safe and selective uterine relaxation when this is indicated in preterm
labour or other obstetric complications.
Background
Preterm labour is a major reproductive health problem
due to a high incidence of severe short- and long-term
infant morbidity. In developed countries, social and med-
ical advances have improved the survival rate of the pre-
term neonate; however, the incidence of preterm birth
and related morbidity remain a serious challenge and the
physiopathological mechanisms of preterm birth are still
a mystery. The use of tocolytic drugs, including those that
operate through cyclic AMP such as beta-mimetics, to
inhibit uterine contractility in preterm labour is contro-
versial because there is no evidence that currently availa-
ble drugs improve long term neonatal outcome.
Moreover, some tocolytics can cause serious side effects
such as tachycardia, hypertension and pulmonary
oedema. The potential of drugs of high uterine selectivity,
e.g. oxytocin receptor antagonists, for the management of
preterm labour is encouraging and further clinical trials
are being undertaken. However, there is a need to identify
novel pharmacological targets in myometrium to provoke
safe and selective uterine relaxation when this is clinically
indicated [1].
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It is not known whether the cause of preterm labour is the
premature loss of uterine quiescence (e.g. removal of
inhibitory factors), or the induction of uterine contractil-
ity (e.g. release of stimulatory mediators) or a combina-
tion of both [2]. The second messenger cyclic adenosine
monophosphate (cAMP) is known to promote the relaxa-
tion of smooth muscle, and is likely to be implicated in
the maintenance of uterine quiescence [2]. Hence, the
study of myometrial cAMP regulatory pathways will help
to understand the mechanism of labour and highlight
possible targets for the development of more specific and
effective tocolytics for preterm labour.
Cyclic AMP signalling pathways
Cyclic AMP is a diffusible intracellular second messenger,
which influences many physiological events, by transduc-
ing hormone and small molecule effects into activation of
protein kinases, modulating calcium transport and regu-
lating gene activation. Its function in the relaxation of
uterine and other types of smooth muscle is believed to be
via inhibition of calcium mobilization and the contractile
apparatus [3], through the activation of cAMP-dependent
protein kinase (PRKA), which phosphorylates target pro-
teins such as myosin light chain kinase (MYLK) [4] and
phospholipase C (PLC) [5] (Table 1 and Figure 1). How-
ever the identification of PRKA substrates in human myo-
metrium is a challenging area of research and more
information is required before the mechanism of cyclic
nucleotide-induced relaxation is understood.
The synthesis and catabolism of cAMP has been studied in
many systems. Adenylyl cyclases (ADCY) catalyse the con-
version of ATP to cAMP in response to the actions of hor-
mones and drugs acting upon cell surface G protein
coupled receptors. The cAMP formed is hydrolysed by a
family of cyclic nucleotide phosphodiesterases (PDE). In
myometrium ADCY activity is induced by endogenous
agonists (catecholamines, prostaglandins, etc) operating
through protein receptors e.g. ADRB2 (β2-adrenoceptor),
PTGER2 (prostaglandin E2 receptor) coupled to Gs [6].
Activated ADCY removes one pyrophosphate molecule to
convert ATP to cAMP and releases it into the cytoplasm.
Cyclic AMP activates PRKA by binding to its catalytic sub-
nits. Spatial and temporal changes in cAMP levels can be
translated into compartmentalised responses by PRKA
anchoring proteins which also bind other protein kinases
and PDE isoforms to regulate a variety of signalling activ-
ities including feedback phosphorylation of ADCY [7].
The concentration of cAMP is reduced rapidly by PDE
hydrolysis. Regulation of PDEs, especially PDE4, the larg-
est myometrial PDE family, is an attractive area of study
because of its potential as a new target for tocolysis. Long
forms of PDE4 are involved in fast cAMP signalling loops
through PRKA activation at conserved phosphorylation
domains, while short forms of PDE4 are associated with
long term responses promoted by cAMP such as gene tran-
scription. Moreover, prostaglandin E2 up-regulates PDE
activity by inducing the synthesis of PDE4 short isoforms
[8].
Adenylyl cyclases and their regulators
Is there a specific myometrial cAMP generation system?
This question is important because it would provide a tar-
get for pharmacological intervention. ADCY are a family
of disparate enzymes directly involved in cAMP synthesis.
The catalytic core of mammalian ADCY consists of a pseu-
dosymmetric heterodimer composed of two highly con-
served cytosolic regions, namely C1a and C2a, which can
bind Gs and ATP. All isoforms of ADCY are activated by
the α subunit of Gs (Gαs) and most are directly activated
by the diterpene forskolin, which is a useful tool for func-
tional studies [9,10]. The C1a and C2a regions alone are
sufficient for cAMP generation, and linkage of portions of
these cytosolic domains yields a soluble form of ADCY,
which is fully activated by both Gαs and forskolin
[11,12].
Table 1: Potential protein kinase A substrates involved in the regulation of human uterine relaxation
Physiological roles (see Shabb (2001) [38]) Protein substrate (HUGO nomenclature) References
Autophosphorylation cAMP dependant protein kinase regulatory subunit type IIα (PRKAR2A) Zakhary et al. (2000) [39]
cAMP signalling β-2 adrenoceptor (ADRB2) Daaka Y et al. (1997) [40]; Iyer et al. (2006) [41]
G protein coupled receptor kinase-2 (ADRBK1) Houslay & Baillie (2006) [42]
Phosphodiesterase 4 (PDE4) Murthy et al. (2002) [43]
Phosphoinositide and calcium signalling InsP3 Type I receptor (ITPR1) Straub et al. (2004) [44]
Phospholipase-C β3 (PLCB3) Yue et al. (1998) [45]
Phospholipase-C γ1 (PLCG1) Park et al. (1992) [46]
ATPase 2 (ATP2) Tribe et al. (2000) [47]
Regulators of G-protein signalling (RGS) Suarez et al. (2003) [48]
Thromboxane A2 receptor (TBXA1R) Walsh et al. (2000) [49]
Rho signalling RhoA small GTP binding protein (RHOA) Murthy et al. (2003) [50]
Gα13 Manganello et al. (2003) [51]
Smooth muscle contraction Myosin light chain kinase (MYLK) Hirano et al. (2004) [52]
Myosin binding subunit of myosin phosphatase (PPP1R12A) Wooldridge et al. (2004) [53]BMC Pregnancy and Childbirth 2007, 7(Suppl 1):S10 http://www.biomedcentral.com/1471-2393/7/S1/S10
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So far, nine mammalian membrane-bound isoforms of
ADCY have been identified, and allocated into one of four
subgroups, according to their modes of regulation [9]
(table 2). All isoforms are activated by Gαs binding pri-
marily to a hydrophobic, negatively charged pocket on the
C2a domain [10]. Since the site of interaction of Gαs with
ADCY is distal to the catalytic site, it has been suggested
that the likely mechanism for Gαs activation involves a
modulation of the structure of the active site by the induc-
tion of a conformational change. All ADCYs, except ADCY
9, which lacks the required serine and leucine residues,
can be activated by forskolin, which binds in a narrow
hydrophobic crevice between the C1a and C2a domains
[13]. Activation of ADCYs by forskolin occurs even in the
absence of a functional G protein, and is, therefore, a con-
sequence of a direct action on the catalytic subunit of the
enzyme [14].
Responses of ADCYs to other modulators can be very dif-
ferent. For example, Group 1 cyclases (ADCY1, ADCY3,
ADCY8) are stimulated by calcium/calmodulin (Ca2+-
CALM) and by PRKA but are inhibited by the α subunits
of proteins of the Gαi/o family and also by G protein βγ
subunits (Gβγ). In contrast, Group 2 isoforms (ADCY2,
ADCY4, and ADCY7) are activated by Gβγ and insensitive
to Ca2+-CALM [15]. Group 3 isoforms (ADCY5 and
ADCY6) are similar to Group 1, in that they are inhibited
by Gαi/o and Gβγ, but they are also inhibited by the pertus-
sis toxin-insensitive inhibitory G-protein Gαz, by low
concentrations of calcium, and by PRKA phosphorylation
Cyclic AMP pathways in myometrial tissue Figure 1
Cyclic AMP pathways in myometrial tissue. Activation of membrane receptors (GPCR) coupled to Gs activates adenylyl 
cyclase (ADCY) which converts ATP to cAMP. The levels of cAMP are tightly regulated by phosphodiesterases (PDE), espe-
cially PDE4 isoforms. It is thought that cAMP induces uterine relaxation via activation of a specific protein kinase (PRKA) which 
phosphorylates and inhibits myosin light chain kinase (MYLK). PRKA may also oppose the effect of stimulatory receptors which 
operate through the phospholipase C (PLC)/calcium pathway. However the precise targets for PRKA phosphorylation in 
human myometrium are under investigation (  stimulation,   inhibition)
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at Ser-674 [16]. ADCY9 belongs in a separate group
because it is insensitive to either calcium or Gαi/o/Gβγ, but
is inhibited by the phosphatase calcineurin [17]. The
effects of protein kinase C (PRKC) on ADCY are very com-
plex and cut across groups. For instance PRKC phosphor-
ylation enhances the activities of ADCY2 and ADCY7
(Group 2) as well as ADCY5 (Group 3). On the other
hand phosphorylation by PRKC reduces the activities of
ADCY4 (Group2) and ADCY6 (Group 3) [9,15]. In preg-
nancy there is upregulation of group 2 and group 3 iso-
forms in myometrium [18], but the question whether
there are dominant ADCY isoforms coupled to specific
myometrial receptors or whether there is promiscuity in
the coupling of GPCR/Gαs complexes to several ADCY
isoforms remains unanswered. The development of sensi-
tive fluorescent tags to study molecular proximity in real
time will help answer this question in myometrial cells.
Phosphodiesterases and their regulators
The phosphodiesterases (PDE) multi-gene family of
enzymes catalyze the hydrolysis of 3',5'-cyclic nucleotides,
and so occupy a key position in modulating intracellular
cyclic nucleotide levels [19]. In myometrial tissue, the
activity of PDE enzymes is significantly inhibited during
pregnancy [20], probably as a consequence of the high
progesterone levels [21], suggesting that cAMP-PDE inhi-
bition may be part of the mechanism for myometrial
relaxation and pregnancy maintenance.
At present, more than 14 PDE genes have been cloned in
mammals and 21 gene products have been identified.
PDE isoforms are grouped in 11 distinct but related fami-
lies (PDE1 to PDE11), according to sequence homology,
substrate specificity, inhibitor sensitivity and function.
Within these families alternative splicing or mRNA tran-
scription initiation result in additional diversity produc-
ing around 100 mRNA products, but it is not clear how
many of these are actually translated into different pro-
teins [19,22]. The protein isoforms all share a common
structural pattern: a C-terminus whose function is unclear;
a conserved catalytic core, which determines substrate
specificity and inhibitor sensitivity; and a divergent N-ter-
minus responsible for the enzyme's targeting [19,22].
PDE subfamilies are differentially expressed in human tis-
sues, and only PDE1-5 subtypes have been detected in
human term myometrium [23]. PDE1 subtypes are of
mixed substrate specificity for cyclic nucleotides (they
tend to hydrolyse either cAMP or cGMP) and contain
auto-inhibitory substrate-like sequences; such inhibition
is relieved by Ca2+/CALM [24]. PDE1 isoforms are clearly
regulated by PRKA and are involved in cell proliferation
[25].
PDE2 and PDE5 have similar structures as both of them
contain allosteric cyclic nucleotide binding sites for
cGMP. The binding of cGMP to PDE2 stimulates cAMP
hydrolysis to mediate cross-talk between cGMP and cAMP
pathways [26,27]. PDE5 expression is inhibited by hCG in
human myometrium [28], and some evidence suggested
that PDE5 may play a role in myometrial cell proliferation
and cGMP dependent potassium channel regulation.
High doses of sildenalfil, a specific PDE5 inhibitor, relax
human pregnant myometrium in vitro, but this effect is
unlikely to be of tocolytic value [29].
PDE3 has two isoforms PDE3A and PDE3B, which con-
tain a conserved catalytic site for both cAMP and cGMP
binding [30]. Functional studies suggest that PDE3 is
involved in vascular smooth muscle contractions, heart
function, platelet aggregation, oocyte maturation and cell
metabolism [31].
PDE4 is the largest PDE subfamily, consisting two classes
of isoforms, long or short PDE4, depending upon the
presence or absence of upstream conserved regions. Both
classes of PDE4 have a much higher affinity for cAMP than
for cGMP [32]. In human myometrial cell, the major
source (up to 75%) of PDE activity is provided by PDE4
isoforms and membrane targeting can influence the max-
imal activity of the enzyme and its sensitivity [23,33].
Early functional studies of PDE4 showed that specific
inhibition with rolipram leads to inhibition of the spon-
taneous contraction of myometrial strips [34,35]. How-
ever, rolipram has significant side effects, particularly
nausea and vomiting. Cilomilast, originally designed as a
novel therapy for asthma with fewer side effects, produces
Table 2: Adenylyl cyclase (ADCY) isoforms
Sub-family Mode of regulation Member Chromosomal localization Referen ces
1 Activated by calcium, Gαs, PRKA inhibited by Gαi/o and Gβγ ADCY1 7p12 Villacres et al. (1993) [54]
ADCY3 5p15 Diel et al. (2006) [55]
ADCY8 2p22-24 Steiner et al. (2006) [56]
2 Activated by Gαs and Gβγ ADCY2 14q11.2 Nguyen & Watts (2006) [57]
ADCY4 3q13.2-q21 Wang & Burns (2006) [58]
ADCY7 12q12-13 Guzman et al. (2005) [59]
3 Activated by Gαs, Inhibited by Gαi/o, Gβγ calcium, PRKA ADCY5 16q12-13 Iwami et al. (1995) [60]
ADCY6 8q24 Chen et al. (1997) [61]
4 Activated by Gαs ADCY9 16p13 Hacker et al. (1998) [62]BMC Pregnancy and Childbirth 2007, 7(Suppl 1):S10 http://www.biomedcentral.com/1471-2393/7/S1/S10
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concentration-dependent inhibition of the spontaneous
contractions of term myometrium [36]. PDE4 selective
inhibitors reduce the incidence of inflammation-induced
preterm delivery in mice [37]. A better understanding of
the regulation of PDE4 isoforms in pregnant human myo-
metrium may be a useful approach to develop tocolytics
of high uterine selectivity [33].
Conclusion
The role of cAMP as an important mediator in the regula-
tion of myometrial function is beyond dispute. Much is
known about the pathways for cAMP synthesis and
hydrolysis. However, the mechanisms of action of cAMP
and its associated kinase PRKA in myometrial cells are not
fully understood. Several candidate PRKA substrates have
been proposed based on studies in other types of smooth
muscle. More research into the identification of physio-
logical PRKA substrates in pregnant human myometrium
and into their regulation by phosphorylation will clarify
the role of cAMP in pregnancy maintenance, and provide
novel targets for uterine-selective therapeutic interven-
tion.
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